Poplar Therapeutics vs Vima Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $95M total ($50M Series A Jan 2026 + $45M extension Mar 2026) from SR One, Vida, RA Capital, Janus Henderson. Triple-action anti-IgE mechanism. Phase 1 data expected H2 2026 for PHB-050.
About
Poplar Therapeutics (formerly Phylaxis Bioscience) raised $95 million in less than 60 days — $50 million in Series A financing in January 2026 from SR One, Vida Ventures, RA Capital, and Janus Henderson, extended by $45 million in March 2026 — reflecting exceptional investor conviction in its PHB-050 anti-IgE program. PHB-050 uses a triple-action anti-IgE mechanism designed to exceed the performance of existing anti-IgE drugs: simultaneously blocking mast cell IgE binding, reducing circulating free IgE, and inhibiting IgE production by B cells. Phase 1 data is expected in the second half of 2026.
Raised $100M Series A extended ($60M + $40M add-on after clinical data) from Atlas, Frazier, Access Industries. Only oral drug in development for isolated dystonia. Phase 2 in dystonia and Parkinson's in 2026.
About
Vima Therapeutics is developing VIM0423, the only oral drug in clinical development for isolated dystonia — a movement disorder characterized by involuntary, sustained muscle contractions affecting approximately 160,000 people in the US, with zero FDA-approved oral treatment options. The company raised a $100 million Series A (extended from $60 million to $100 million after positive clinical data) from Atlas Venture, Frazier Life Sciences, and Access Industries. VIM0423 is entering Phase 2 trials in both isolated dystonia and Parkinson's disease tremor in 2026.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.